Clinical trial
Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver
NCT04628871 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver
- Lead sponsor
- Sangamo Therapeutics
- Phase
- Observational
- Overall status
- Terminated
- Start date
- November 3, 2020
- Completion date
- June 17, 2026
- Enrollment
- 13 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.